# Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment

> **NCT00881205** · PHASE4 · TERMINATED · sponsor: **Novartis Pharmaceuticals** · enrollment: 86 (actual)

## Conditions studied

- Multiple Sclerosis
- Cognitive Impairment

## Interventions

- **DRUG:** Rivastigmine transdermal patch
- **DRUG:** Placebo

## Key facts

- **NCT ID:** NCT00881205
- **Lead sponsor:** Novartis Pharmaceuticals
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE4
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2009-04
- **Primary completion:** 2011-01
- **Final completion:** 2011-01
- **Target enrollment:** 86 (ACTUAL)
- **Why stopped:** Termination of study due to low enrollment
- **Last updated:** 2012-03-12


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00881205

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00881205, "Rivastigmine in Multiple Sclerosis Patients With Cognitive Impairment". Retrieved via AI Analytics 2026-07-26 from https://api.ai-analytics.org/clinical/NCT00881205. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*